Share Name Share Symbol Market Type Share ISIN Share Description
Deepmatter Group Plc LSE:DMTR London Ordinary Share GB00B29YYY86 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 2.00 504,813 11:38:49
Bid Price Offer Price High Price Low Price Open Price
1.80 2.20 2.00 1.85 2.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals -1.99 -0.33 15
Last Trade Time Trade Type Trade Size Trade Price Currency
11:38:24 O 24,195 2.05 GBX

Deepmatter (DMTR) Latest News

More Deepmatter News
Deepmatter Takeover Rumours

Deepmatter (DMTR) Discussions and Chat

Deepmatter Forums and Chat

Date Time Title Posts
08/4/202016:34DeepMatter 125

Add a New Thread

Deepmatter (DMTR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-04-08 10:38:262.0524,195496.00O
2020-04-08 10:11:432.0524,195496.00O
2020-04-08 09:29:062.0520,000410.00O
2020-04-08 09:16:362.0534,146699.99O
2020-04-08 09:13:581.9870,2461,390.87O
View all Deepmatter trades in real-time

Deepmatter (DMTR) Top Chat Posts

Deepmatter Daily Update: Deepmatter Group Plc is listed in the Chemicals sector of the London Stock Exchange with ticker DMTR. The last closing price for Deepmatter was 2p.
Deepmatter Group Plc has a 4 week average price of 1.55p and a 12 week average price of 1.55p.
The 1 year high share price is 4.30p while the 1 year low share price is currently 1.55p.
There are currently 736,528,946 shares in issue and the average daily traded volume is 244,695 shares. The market capitalisation of Deepmatter Group Plc is £14,730,578.92.
noirua: Group PLC DeepMatter collaboration with AstraZeneca 9 December 2019 DeepMatter's DigitalGlassware(TM) data collection and structuring technology to be used alongside AstraZeneca's automated compound synthesis platform Scientists from the two organisations will work together to improve the productivity of synthesising single compounds and compound libraries based on unique, structured data harvested from the DigitalGlassware(TM) technology. Michael Kossenjans, Associate Director, Discovery Sciences, R&D, AstraZeneca, said: "Our goal is to transform drug design using innovative digital technologies in combination with automation and AI. To get potential new medicines to patients faster, we need to reduce the cycle time for lead identification and optimisation and look forward to working with DeepMatter to assess the potential of DigitalGlassware(TM) to help with this." Mark Warne, CEO of DeepMatter, said: "We've been impressed with the automated chemistry platforms developed at AstraZeneca sites for autonomous delivery of new lead series. We see an opportunity to draw together knowledge from the DigitalGlassware(TM) platform to enable machine learning and AI technologies to increase the certainty of producing a high quality and choice of candidate drug molecules. "We look forward to progressing this exciting collaboration over the coming months as we continue to maximise the potential of the DigitalGlassware(TM) platform."
mcrudden: Added more here today, looking at the share price you'd think that nothing had happened this week. Strange
Deepmatter share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200409 02:36:34